Related Experiment Video
Updated: Aug 2, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Long-acting antiretrovirals and HIV treatment adherence
Jean B Nachega1, Kimberly K Scarsi2, Monica Gandhi3
1Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA; Department of Infectious Diseases and Microbiology, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA; Center for Global Health, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA; Department of Epidemiology and Department International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Insights
Long-acting injectable antiretroviral therapy (ART) offers a new option for HIV treatment, reducing injections from daily pills to monthly or bimonthly doses. Further research is needed to confirm its effectiveness and cost-efficiency across diverse patient groups and settings.
Area of Science:
- Infectious Diseases
- Pharmacology
- Public Health
Background:
- Long-acting injectable antiretroviral therapy (ART) represents a significant advancement in HIV management.
- Current daily oral ART regimens require consistent adherence, posing challenges for some individuals.
- The development of long-acting formulations aims to improve treatment convenience and adherence.
Purpose of the Study:
- To introduce the novel long-acting injectable combination of cabotegravir and rilpivirine for HIV treatment.
- To highlight the potential of long-acting ART to revolutionize HIV care, prevention, and treatment.
- To identify areas requiring further investigation for widespread adoption of long-acting ART.
Main Methods:
- The abstract discusses the approval and use of intramuscular injections of long-acting cabotegravir and rilpivirine.
- It reviews the reduced dosing frequency from daily oral intake to monthly or bimonthly injections.
- The text implies a review of existing data and clinical development stages for long-acting ART.
Main Results:
- Long-acting cabotegravir with rilpivirine is approved as a fully suppressive HIV regimen.
- Dosing frequency is reduced to once every month or every two months.
- This marks a new era with other long-acting antiretrovirals in development.
Conclusions:
- Long-acting ART holds immense promise for transforming HIV treatment standards.
- More data are essential to confirm efficacy and cost-effectiveness in specific populations (e.g., those at risk of non-adherence, different age groups, pregnant/postpartum individuals).
- Policy changes and advocacy are crucial for equitable global access, particularly in low- and middle-income countries.
Abstract:
Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for people living with HIV. Long-acting cabotegravir with rilpivirine ART has reduced required dosing frequency from once daily to once every month or every 2 months injections. This new era of long-acting ART, which includes other antiretrovirals and formulations in various stages of clinical development, holds tremendous promise to change the standard of HIV treatment. Although long-acting ART has high potential to be revolutionary in the landscape of HIV care, prevention, and treatment cascade, more data are needed to substantiate its efficacy and cost-effectiveness among patients at risk of non-adherence and across age groups, pregnancy, and post partum. Advocacy efforts and policy changes to optimise a sustained, high-quality, equitable reach of long-acting ART, especially in low-income and middle-income countries where most people living with HIV reside, are needed to realise the full benefits of long-acting ART.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Drug Therapy
Antianxiety Medications
Sexually Transmitted Infections
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Size and Structure of Viral Genomes

